Cabotegravir implant (Preclinical)
IAVI W001
HVTN 302
RV 546
Enhancing HIV Prevention with Injectable Preexposure Prophylaxis
Quarraisha Abdool Karim, Ph.D. writes about the results of HPTN 083 and the implications of long-acting injectable of PrEP with cabotegravir in the New England Journal of Medicine.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.
Voluntary Medical Male Circumcision for HIV Prevention (VMMC): An introductory factsheet
This introductory 2-page document explains how VMMC works, reviews the scientific evidence behind it, and outlines key advocacy issues for implementing it.
2018 and HIV Prevention: AVAC’s Take
In this episode hear about recently published findings from a study out of Rakai, Uganda confirm that scaling up of a combination of existing interventions, such as voluntary medical male circumcision and antiretroviral therapy provides protection from HIV at the population-level. How do we apply these findings at the global level? How should advocates prepare for results—anticipated in 2019—of the ECHO trial that’s looking at the effect of hormonal contraceptives on HIV risk? And what needs to happen in 2018 to reach long-term global targets for ending the epidemic?
Slow and Steady Won’t Win the Prevention Race
Progress in voluntary medical male circumcision has made significant gains but still fell short of targets—or why VMMC isn’t a global priority and how to make it one. Excerpted from AVAC Report 2016: Big Data, Real People.
Voluntary Medical Male Circumcision: What Gets Counted
This table from Px Wire January-March 2014 Volume 7, No.1 examines why the global systems for tracking voluntary medical male circumcision are lagging behind the actual progress being made.